Context Therapeutics (NASDAQ: CNTX) posts updated January 2026 investor deck

Rhea-AI Filing Summary

Context Therapeutics Inc. furnished an updated corporate presentation dated January 2026 for use in meetings with investors, analysts and other stakeholders. The presentation is provided as Exhibit 99.1 to this report and is incorporated by reference for informational purposes. The company states that the materials in Item 7.01 and Exhibit 99.1 are being furnished, not filed, meaning they are not subject to certain liability provisions of the Exchange Act and are not automatically incorporated into other Securities Act or Exchange Act filings.

0001842952FALSE00018429522026-01-082026-01-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2026

Context Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Delaware			001-40654			86-3738787
(State of other jurisdiction of incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

2001 Market Street, Suite 3915, Unit #15

Philadelphia, Pennsylvania 19103

(Address of principal executive offices including zip code)

(267) 225-7416

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class

Trading Symbol

Name of exchange on which registered

Common Stock

CNTX

The Nasdaq Stock Market

$0.001 par value per share

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On January 8, 2026, Context Therapeutics Inc. (the "Company") updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information in this Item 7.01, and Exhibit 99.1 attached hereto, are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Context Therapeutics Inc. Corporate Presentation — January 2026
104						Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 8, 2026			Context Therapeutics Inc.
			By:			/s/ Martin A. Lehr
						Name: Martin A. Lehr
						Title: Chief Executive Officer

FAQ

What did Context Therapeutics (CNTX) disclose in this 8-K filing?

Context Therapeutics Inc. disclosed that it has updated its corporate presentation for use in meetings with investors, analysts and others, and furnished it as Exhibit 99.1 to the report.

How is the new Context Therapeutics (CNTX) presentation made available?

The updated Context Therapeutics corporate presentation is attached to the report as Exhibit 99.1 titled “Context Therapeutics Inc. Corporate Presentation — January 2026.”

Is the Context Therapeutics (CNTX) investor presentation considered “filed” with the SEC?

No. The company states that Item 7.01 and Exhibit 99.1 are being furnished and not deemed filed under Section 18 of the Exchange Act, and are not automatically incorporated into other Securities Act or Exchange Act filings.

What is the purpose of Context Therapeutics’ updated January 2026 presentation?

The updated January 2026 corporate presentation is intended for use in meetings with investors, analysts and others, providing an updated overview of Context Therapeutics Inc. and its activities.

Who signed this Context Therapeutics (CNTX) 8-K report?

The report was signed on behalf of Context Therapeutics Inc. by Martin A. Lehr, who is identified as the company’s Chief Executive Officer.

Does this Context Therapeutics (CNTX) 8-K include new financial statements?

No additional financial statements are listed. Under Item 9.01(d), the report identifies only Exhibit 99.1 (the corporate presentation) and the Cover Page Interactive Data File as exhibits.